ResultsCNBC-TV18
Glenmark Pharma shares react to better-than-expected US sales in Q2
Negative-14Company event
GreyOak summary
Glenmark Pharmaceuticals reported September quarter results with revenue exceeding estimates, though consolidated net profit declined 56.7% to ₹264 crore. India business revenue grew 704% YoY, with the formulation segment up 14% on a like-for-like basis. EBITDA fell 63.4% to ₹864 crore.
What it affects
- Glenmark PharmaceuticalsGLENMARKNegative -14
Net profit fell 56.7%Rolling sentiment Negative -54
Source
Read the original at CNBC-TV18More Glenmark Pharmaceuticals news
- Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · Stock view ·
- Motilal Oswal sets Glenmark Pharma target at Rs 3000Moneycontrol · Company update ·
- Pharma stocks rally: Aurobindo, Divi's, Glenmark, Symbiotec hit new highsBusiness Standard · Stock view ·
- Glenmark Pharma shares fall 4% after Q2 profit plunges 57%Business Today · Results ·
- Titan, Bharti, Britannia, Glenmark, Godfrey, NCC, KNR, Ashoka focusMoneycontrol · Stock view ·